Global Anti-Idiopathic Pulmonary Fibrosis Durgs Market Set To Grow To $4.1bn By 2022

06 August 2018
Pharma

Visiongain’ has launched a new pharma report Global Anti-Idiopathic Pulmonary Fibrosis Drugs Market : Antifibrotics, Tyrosine Kinase Inhibitors, Anti-inflammatory Drugs, Immunosuppressants, Other MoA, Innovator Drugs, Off-label Drugs

This report is intended to provide an in-depth analysis of the latest trends of the Global Anti-Idiopathic Pulmonary Fibrosis Drugs Market and its growth and development in the next decade. The changing demographics of the world population, emerging economies, consumer spending behaviour, per capita income, macroeconomic factors, rising GDPs, and the reformation in laws and regulations are trend setting factors, which will affect the market.

This report examines in detail the market forecast by geography, by mechanism of action, as well as by innovator & off-label drugs during 2017-2027, providing the reader with a thorough overview of the market to identify key growth areas and business opportunities.

The lead analyst of the report commented “The global anti-idiopathic pulmonary fibrosis drugs market is driven by the rising prevalence and incidence of IPF patients, expected launch of novel therapies, special regulatory (Orphan and Fast-track) designations for pipeline molecules, increased understanding of disease pathogenesis, and limited number of current players.
However, the growth of this market might be slowed down by various challenges during the forecast period with use of off-label drugs, availability of non-pharmacological therapies, and lack of proper diagnosis techniques as well as the absence of highly efficacious & safe drugs.”

Leading companies featured in the report include Actelion, Afferent Pharmaceuticals, Asahi Kasei Pharma, Bellerophon Therapeutics, Biogen, Boehringer Ingelheim, FibroGen, Galapagos, Galecto Biotech, Genentech, Global Blood Therapeutics, GSK, Kadmon Pharmaceuticals, LTT, Bio-Pharma, MediciNova, Merck, Moerae, Pacific Therapeutics, Promedior, ProMetic Life Sciences, Roche, Sanofi, Teva, Zai Lab

Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to sara.peerun@visiongainglobal.com or call her on +44 (0) 207 336 6100

About visiongain
Visiongain is one of the fastest-growing and most innovative independent media companies in Europe. Based in London, UK, visiongain produces a host of business-to-business reports cusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.

Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.

Recent News

Visiongain Publishes Decentralized Clinical Trials Market Report 2022-2032

The growing adoption advanced e-clinical solutions, rising focus on clinical research, increasing investment in R&D, and adoption of decentralized clinical trials by biopharmaceutical companies are some of the major factors that drive the growth of the global decentralized clinical trials market.

24 January 2022

Read

Visiongain Publishes Nasal Drug Delivery Technology Market Report 2022-2032

The nasal drug delivery market will expand rapidly due to rising patient preference for nasal medication delivery due to ease of administration and efficacy, increased self-administration practises, and increased demand for home healthcare equipment.

18 January 2022

Read

Visiongain Publishes Deep Frozen Packaging Logistics Market Report 2022-2032

The desire for various types of medications to assist combat a growing number of chronic diseases & lifestyle-related ailments is fuelling the overall deep freeze packaging logistics market demand.

14 January 2022

Read

Visiongain Publishes Pre-Filled Syringes Market Report 2022-2032

With COVID-19 pandemic, the prefilled syringes business has witnessed a significant growth. Since the outbreak of the pandemic, global market players involved in the development of the prefilled syringes market across the globe have increased their investment in raw materials and resources owing to the rise in demand for home based healthcare services.

11 January 2022

Read

Kelloggs
3m
Thales
Shell
TEVA
Lockheed-Martin
Pfizer
Raytheon
Halliburton
Du-Pont
Honeywell
Daimler
BASF
Bayer
BP
BAE-Systems
Unilever